Siglec‐7 and Siglec‐9 expression in primary triple negative and oestrogen receptor positive breast cancer and <i>in vitro</i> signalling
These data imply that immunotherapy targeting Siglec receptors may be particularly interesting for TN breast cancer patients not responding to current treatment strategies with tumors displaying high immune cell infiltration.
Authors
- Jasper Lok
- Anne HC Valk (ORCID: https://orcid.org/0000-0002-6190-0438)
- Gosse J. Adema (ORCID: https://orcid.org/0000-0002-6750-1665)
- Lenneke A. M. Cornelissen (ORCID: https://orcid.org/0000-0003-2210-1606)
- Daniel Granado
- Naomi Remkes (ORCID: https://orcid.org/0009-0009-0221-6255)
- Eline J.H. van Houtum (ORCID: https://orcid.org/0000-0001-9037-4388)
- Jesper van Eck van der Sluijs (ORCID: https://orcid.org/0000-0003-3136-7799)
- Paul N. Span (ORCID: https://orcid.org/0000-0002-1930-6638)
- Lune van den Bogaard (ORCID: https://orcid.org/0009-0004-9060-2925)
Institutions
- Radboud University Nijmegen (NL)
- Radboud University Medical Center (NL)
Publication Details
- Journal
- Clinical & Translational Immunology
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/cti2.1524
- Citations
- 6
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- KWF Kankerbestrijding
- Radboud Universitair Medisch Centrum